BR112022026067A2 - Agentes de proteção de células endoteliais vasculares, da barreira hematoencefálica da medula espinhal e do sistema nervoso central, e, composição farmacêutica para prevenir e/ou tratar uma doença acompanhada de um distúrbio da barreira hematoencefálica da medula espinhal - Google Patents
Agentes de proteção de células endoteliais vasculares, da barreira hematoencefálica da medula espinhal e do sistema nervoso central, e, composição farmacêutica para prevenir e/ou tratar uma doença acompanhada de um distúrbio da barreira hematoencefálica da medula espinhalInfo
- Publication number
- BR112022026067A2 BR112022026067A2 BR112022026067A BR112022026067A BR112022026067A2 BR 112022026067 A2 BR112022026067 A2 BR 112022026067A2 BR 112022026067 A BR112022026067 A BR 112022026067A BR 112022026067 A BR112022026067 A BR 112022026067A BR 112022026067 A2 BR112022026067 A2 BR 112022026067A2
- Authority
- BR
- Brazil
- Prior art keywords
- spinal cord
- nervous system
- central nervous
- pharmaceutical composition
- barrier
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 239000003223 protective agent Substances 0.000 title abstract 5
- 210000000278 spinal cord Anatomy 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000008499 blood brain barrier function Effects 0.000 title abstract 3
- 210000001218 blood-brain barrier Anatomy 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 210000003556 vascular endothelial cell Anatomy 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 2
- 239000005462 Mubritinib Substances 0.000 abstract 2
- 229910052797 bismuth Inorganic materials 0.000 abstract 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 2
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 abstract 2
- 229960001210 brexpiprazole Drugs 0.000 abstract 2
- 230000006735 deficit Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 abstract 2
- 229950002212 mubritinib Drugs 0.000 abstract 2
- 229960001789 papaverine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 AND Substances 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010028570 Myelopathy Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
AGENTES DE PROTEÇÃO DE CÉLULAS ENDOTELIAIS VASCULARES, DA BARREIRA HEMATOENCEFÁLICA DA MEDULA ESPINHAL E DO SISTEMA NERVOSO CENTRAL, E, COMPOSIÇÃO FARMACÊUTICA PARA PREVENIR E/OU TRATAR UMA DOENÇA ACOMPANHADA DE UM DISTÚRBIO DA BARREIRA HEMATOENCEFÁLICA DA MEDULA ESPINHAL. A presente invenção refere-se a um agente de proteção de células endoteliais vasculares, um agente de proteção de barreira hematoliquórica e um agente de proteção do sistema nervoso central, compreendendo pelo menos um composto selecionado do grupo que consiste em mubritinib, brexpiprazol, papaverina, compostos contendo bismuto e sais farmaceuticamente aceitáveis dos mesmos. Adicionalmente, a presente invenção refere-se a uma composição farmacêutica para prevenir e/ou tratar doenças associadas a deficiências na barreira hematoliquórica, tais como danos ao sistema nervoso central, infarto e hemorragia, doenças inflamatórias do sistema nervoso central, doenças degenerativas do sistema nervoso central, doenças nervosas sintomáticas, deficiências da medula espinhal associadas à degeneração da medula espinhal, deficiências causadas por fármacos, doenças infecciosas ou anafilaxia. A composição farmacêutica compreende pelo menos um composto selecionado do grupo que consiste em mubritinib, brexpiprazol, papaverina, compostos contendo bismuto e sais farmaceuticamente aceitáveis dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020109190 | 2020-06-24 | ||
| PCT/JP2021/024033 WO2021261571A1 (ja) | 2020-06-24 | 2021-06-24 | 血液脳脊髄関門保護剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026067A2 true BR112022026067A2 (pt) | 2023-01-17 |
Family
ID=79281374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026067A BR112022026067A2 (pt) | 2020-06-24 | 2021-06-24 | Agentes de proteção de células endoteliais vasculares, da barreira hematoencefálica da medula espinhal e do sistema nervoso central, e, composição farmacêutica para prevenir e/ou tratar uma doença acompanhada de um distúrbio da barreira hematoencefálica da medula espinhal |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230106974A1 (pt) |
| EP (1) | EP4173620A1 (pt) |
| JP (1) | JPWO2021261571A1 (pt) |
| CN (1) | CN116113412A (pt) |
| BR (1) | BR112022026067A2 (pt) |
| WO (1) | WO2021261571A1 (pt) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63174926A (ja) * | 1987-01-09 | 1988-07-19 | Nitto Kasei Kk | 家禽用抗コクシジウム剤 |
| EP1531837A4 (en) * | 2001-06-07 | 2006-11-15 | Chiou Consulting Inc | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF APHTEOUS ULCERS AND LESIONS DUE TO HERPES |
| JP5674166B2 (ja) | 2010-12-13 | 2015-02-25 | 学校法人福岡大学 | 血液脳関門障害症候群治療薬 |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| JP2015134732A (ja) * | 2014-01-17 | 2015-07-27 | 国立大学法人大阪大学 | 血管透過性亢進抑制剤 |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| KR20200103680A (ko) * | 2017-12-21 | 2020-09-02 | 글리아팜 에스에이 | 치매를 포함하는 신경 장애에 대한 치료 조성물 및 방법 |
-
2021
- 2021-06-24 BR BR112022026067A patent/BR112022026067A2/pt unknown
- 2021-06-24 CN CN202180051734.0A patent/CN116113412A/zh active Pending
- 2021-06-24 US US17/642,287 patent/US20230106974A1/en active Pending
- 2021-06-24 EP EP21828655.7A patent/EP4173620A1/en active Pending
- 2021-06-24 WO PCT/JP2021/024033 patent/WO2021261571A1/ja unknown
- 2021-06-24 JP JP2022502997A patent/JPWO2021261571A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230106974A1 (en) | 2023-04-06 |
| JPWO2021261571A1 (pt) | 2021-12-30 |
| CN116113412A (zh) | 2023-05-12 |
| WO2021261571A1 (ja) | 2021-12-30 |
| EP4173620A1 (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dai et al. | Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress | |
| Perkins et al. | New insights into mitochondrial structure during cell death | |
| Campolo et al. | Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice | |
| Salar et al. | Blood–brain barrier dysfunction can contribute to pharmacoresistance of seizures | |
| Dorandeu et al. | Efficacy of the ketamine–atropine combination in the delayed treatment of soman-induced status epilepticus | |
| BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
| BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
| JP2012214516A (ja) | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 | |
| Shu et al. | Inhibition of neuron-specific CREB dephosphorylation is involved in propofol and ketamine-induced neuroprotection against cerebral ischemic injuries of mice | |
| PT660707E (pt) | Amantadina e compostos relacionados para utilizacao no tratamento da neuropatia periferica | |
| BR9916197A (pt) | Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| Xu et al. | Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage | |
| BRPI0602338A (pt) | compostos orgánicos | |
| BR112014030325A2 (pt) | composição farmacêutica para tratar ou prevenir doença neurodegenerativa e alimento funcional | |
| Wu et al. | Effect of combined treatment with methylprednisolone and Nogo-A monoclonal antibody after rat spinal cord injury | |
| Pernici et al. | Longitudinal optical imaging technique to visualize progressive axonal damage after brain injury in mice reveals responses to different minocycline treatments | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| BR112022026067A2 (pt) | Agentes de proteção de células endoteliais vasculares, da barreira hematoencefálica da medula espinhal e do sistema nervoso central, e, composição farmacêutica para prevenir e/ou tratar uma doença acompanhada de um distúrbio da barreira hematoencefálica da medula espinhal | |
| Stack et al. | Huntington's disease: progress and potential in the field | |
| Paliwal et al. | Pharmacokinetic study of piracetam in focal cerebral ischemic rats | |
| BR112013032911A2 (pt) | leucotoxina e/d como um novo agente anti-inflamatório e microbicida | |
| BR112022014925A2 (pt) | Inibidores macrocíclicos de rip2-quinase | |
| CA2720670A1 (en) | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |